CTIS2022-502156-31-00招募中1 期
A phase 1/2 open-label study of Debio 0123 in combination with temozolomide in adult participants with recurrent or progressive glioblastoma and of Debio 0123 in combination with temozolomide and radiotherapy in adult participants with newly diagnosed glioblastoma - Debio 0123-GBM-105
Debiopharm International S.A.0 个研究点目标入组 48 人开始时间: 2023年1月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Phase 1 and Phase 2 Signed written informed consent approved before undertaking any study-specific procedures., Phase 1 and Phase 2 Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures., Additional specific criteria for Phase 1 Arm A Participants must have one of the following histopathologically proven diagnoses (WHO 2021) • GBM IDH-wildtype, Grade 4, which may include secondary GBMs (i.e., those that progress from low-grade gliomas) • Astrocytoma, IDH-mutant, Grade 3, Additional specific criteria for Phase 1 Arm B/C: Participants must have a new, histopathologically proven diagnosis (WHO 2021) of GBM, IDH-wildtype, Grade 4, which may include secondary GBMs (i.e., those that progress from low-grade gliomas)., Additional specific criteria for Phase 1 Arm A/dose expansion and Phase 2 A maximum of 1 (Phase 1 dose expansion and Phase 2) or 2 (Phase 1 Arm A) prior treatment lines of which first-line must be treatment with TMZ-based chemoradiotherapy (TMZ concomitantly with RT), Additional specific criteria for Phase 1 Arm A/dose expansion and Phase 2 Documented disease recurrence or progression by diagnostic biopsy or Gd-based contrast-enhanced brain MRI as per RANO criteria., Additional specific criteria for Phase 1 Arm A/dose expansion and Phase 2 C) KPS =60., Additional specific criteria for Phase 1 Arm B/C B) KPS =70., Additional specific criteria for Phase 1 dose expansion and Phase 2 Participants must have a histopathologically proven diagnosis (WHO 2021) of GBM, IDH-wildtype, Grade 4., Phase 1 and Phase 2 Age =18 years of age., Phase 1 and Phase 2 Willing to provide archived or fresh tumor sample, if available. Receipt of tumor sample is not required for the start of study treatment., Phase 1 and Phase 2 Adequate bone marrow, hepatic, and renal function, Phase 1 and Phase 2 Life expectancy of at least 3 months in the best judgment of the Investigator, Phase 1 and Phase 2 Participants receiving corticosteroids must be on a stable or decreasing dose of =4 mg daily dexamethasone (or =25 mg prednisone) for the 7 days prior to the start of study treatment., Phase 1 and Phase 2 Participants with seizures must be adequately controlled on a stable regimen of anti-epileptic drugs., Phase 1 and Phase 2 Measurable or non-measurable disease per RANO criteria by gadolinium (Gd)-based contrast-enhanced brain magnetic resonance imaging (MRI)., Phase 1 and Phase 2 Willing to practice highly effective methods of contraception.
排除标准
- •Phase 1 and Phase 2 History of other malignancies requiring active treatment in the last 2 years prior to the first dose of study treatment except for superficial bladder cancers, adequately treated low-risk prostate cancer under active surveillance, ductal carcinoma in situ or other carcinomas in situ, and non-melanoma skin cancers (basal cell/squamous cell skin cancer) that have been treated with curative intent., Specific criteria for Phase 1 Arm A Prior TMZ-related hematological event leading to discontinuation of TMZ during the concurrent chemoradiotherapy., Additional specific criteria for Phase 1 Arm B/C Prior radiation, chemotherapy, biological therapy, interstitial brachytherapy, implanted chemotherapy, therapeutics delivered by local injection or convection-enhanced delivery for GBM., Specific criteria for Phase 1 Arm B/C Prior therapy that would result in an overlap of the radiation fields., Additional specific criteria for Phase 1 dose expansion and Phase 2 Prior treatment with more than 1 line of systemic therapy for GBM, IDH-wildtype, Grade 4. Combination therapy with TMZ and RT with or without subsequent TMZ maintenance treatment is considered as 1systemic line, Phase 1 and Phase 2 Known contraindication for Gd-based, contrast-enhanced MRI., Phase 1 and Phase 2 Left ventricular ejection fraction (LVEF) below 55%., Phase 1 and Phase 2 Exposure to high levels of ultraviolet (UV) light, for example occupational exposure to sunlight or sunbathing., Phase 1 and Phase 2 Chemotherapy, monoclonal antibodies/biologics, investigational treatment, or RT with curative intent within 28 days prior to starting study treatment., Phase 1 and Phase 2 Hypersensitivity to Debio 0123, TMZ, dacarbazine, or any of the excipients found in the formulation for Debio 0123 or TMZ, Phase 1 and Phase 2 Prior exposure to any WEE1 inhibitor, Additional specific criteria for Phase 1 Arm A Prior treatment with more than 2 lines of therapy for GBM IDH-wildtype, Grade 4, or for astrocytoma, IDH-mutant, Grade 3., Specific criteria for Phase 1 Arm A Prior treatment with bevacizumab or with other vascular endothelial growth factor (VEGF) inhibitors or VEGF-receptor signaling inhibitors.
研究者
相似试验
招募中
1 期
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade IIINCT05765812Debiopharm International SA116
招募中
不适用
A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors.Advanced Malignancy / Cancer10027655NL-OMON56391Debiopharm81
进行中（未招募）
1 期
A study evaluating the impact of Itacitinib when added to Ibrutinib for the treatment of relapsed or refractory diffuse large B-Cell lymphomaEUCTR2017-002773-19-ITINCYTE CORPORATIO78
进行中（未招募）
1 期
A study evaluating the impact of Itacitinib when added to Ibrutinib for the treatment of relapsed or refractory diffuse large B-Cell lymphomaRelapsed or refractory diffuse large B-cell lymphomaMedDRA version: 20.0 Level: PT Classification code 10012822 Term: Diffuse large B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10012821 Term: Diffuse large B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002773-19-GBIncyte Corporation78
进行中（未招募）
1 期
A study evaluating the impact of Itacitinib when added to Ibrutinib for the treatment of relapsed or refractory diffuse large B-Cell lymphomaRelapsed or refractory diffuse large B-cell lymphomaMedDRA version: 20.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10012821Term: Diffuse large B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002773-19-BEIncyte Corporation78